Jörn M. Schattenberg, M.D. received his medical degree from the University of Mainz, Germany in 2002 after studying Medicine in Mainz (Germany) and at the Tulane University in New Orleans (US) . He completed his postdoctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signaling pathways involved in the pathophysiology of acute and chronic liver injury with a special focus on metabolic liver disease and NASH. Since 2004 he is a clinical physician and hepatology consultant for in- and out-patients at the University Medical Center Mainz, trained and board-certified in internal medicine and gastroenterology & hepatology and infectious disease. He leads a research laboratory focusing on clinical and experimental aspects of metabolic and toxic liver injury, the development of therapeutic intervention and novel biomarkers in NASH. In 2013 he was appointed Assistant professor. He serves as lead and national PI in phase II and III clinical trials in NASH and is a member of the EU-funded H2020 EPOS Program (Elucidating Signaling pathways in NASH) and member of the executive committee of the LITMUS consortium for the validation of biomarkers in NASH.